Navigation Links
Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
Date:5/28/2013

PRINCETON, N.J., May 28, 2013 /PRNewswire/ -- Omthera Pharmaceuticals, Inc. (Nasdaq: OMTH), an emerging specialty pharmaceutical company, today announced its financial results for the first quarter of 2013.

Omthera Pharmaceuticals also announced today that it had entered into a definitive merger agreement with AstraZeneca pursuant to which AstraZeneca will acquire Omthera for $12.70 per share, or approximately $323 million. In addition to the cash payment, each Omthera stockholder will receive one Contingent Value Right (CVR) of up to approximately $4.70 for each share they own, equating to $120 million, if specified milestones related to Epanova are achieved, or if a milestone related to global net sales is achieved. This will bring the total potential acquisition value to $443 million.

First Quarter 2013 Financial Results

  • Omthera reported a net loss of $6.3 million for the first quarter of 2013, compared to a net loss of $9.2 million for the first quarter of 2012. Net loss applicable to common stockholders for the first quarter of 2013 was $7.3 million, or $3.08 per common share, compared to a net loss of $10.1 million, or $6.18 per common share, for the first quarter of 2012.
  • Research & Development expenses totaled $0.4 million for the first quarter of 2013, compared to $8.0 million for the first quarter of 2012. The amounts for the first quarter of 2013 and 2012 include approximately $0.1 million and $0.1 million of non-cash stock-based compensation expense, respectively. The decrease in Research & Development expenses is primarily due to the completion in 2012 of the Phase III clinical trials associated with Epanova, compared to current period expenses devoted largely to moving Epanova to regulatory approval.
  • General & Administrative expenses totaled $1.3 million for the first quarter of 2013, comp
    '/>"/>

  • SOURCE Omthera Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
    2. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
    3. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
    4. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
    5. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
    6. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    7. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
    8. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
    9. Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Worth $825 Million by 2017
    10. Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference
    11. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by AstraZeneca ... is an important drug for the treatment of ... 2000, quetiapine was listed in the Catalogue of ...
    (Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... selective prostaglandin receptor agonist which effectively reduces intraocular ... by FDA, latanoprost (under the trade name of ...
    (Date:8/28/2015)... KONG , August 28, 2015 ... in collaboration with one of the leading academics in ... (current world record holder in life extension for model ... insights into biology of aging and age-related diseases, primarily, around ... The work has just been published as "Stability analysis of ...
    Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3
    ... At the end of 2009, the vaccine industry raised ... business media were occupied by various kinds of news ... successfully landed on the Nasdaq, then Simcere, a pharmaceutical ... announced a 50.8% stake in Ealong Biotech and took ...
    ... EAST HANOVER, N.J., Oct. 16 Novartis announced today ... safety profile of once-yearly Reclast® (zoledronic acid) injection in ... 1,200 women was presented this weekend at the annual ... Research (ASBMR) in Toronto, ON, Canada. The ...
    Cached Medicine Technology:Vaccine Leaders All Over the World Talking About China Vaccine Opportunities at VacChina 2010 -- the No.1 China Focused Vaccine Partnering Forum 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 2Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 3Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 4Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 5Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis 6
    (Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s largest travel ... in Healthcare by Modern Healthcare and will be honored at an awards dinner ... year, the Best Places to Work in Healthcare program recognizes outstanding employers in the ...
    (Date:8/28/2015)... ... August 28, 2015 , ... ... for its adolescent residential, counseling, day treatment and intensive family based services. , ... standards for quality and its pursuit of excellence. As a nonprofit charity for ...
    (Date:8/28/2015)... ... August 28, 2015 , ... SmartPractice ... low cost. Personalized with practice contact information and logos, Calendars stand alone as ... also incorporate Calendars into seasonal mailings, thank you and welcome communications, and to ...
    (Date:8/28/2015)... ... 28, 2015 , ... Northridge dentists Dr. Elyson and Dr. Assili ... patients can currently receive a one hour treatment of this teeth whitening option. ... a number of unique features that can turn teeth up to nine shades whiter. ...
    (Date:8/28/2015)... ... August 28, 2015 , ... SharkNinja, an ... coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® brand’s ... Extraction™ technology, which delivers a variety of sizes and styles while achieving the ...
    Breaking Medicine News(10 mins):Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3
    ... of California, chemists have taken snapshots of the ... professor of chemistry at the UC Berkeley, reported ... than the width of a human hair an ... generated great excitement in the opto-electronics community because ...
    ... strategy was developed - using a natural compound to ... in the cellular reservoirs of the body. Prostratin, an ... stimulate the virus, which causes AIDS, in a way ... attack it.// , Dr. Roger Pomerantz, chief of ...
    ... to a study, exercise can help older people avert ... such as standing up and walking an impossible one.Those ... likely to lose abilities to perform activities of daily ... of Medicine, Texas, this report is the first to ...
    ... identified a gene that causes benign moles on the skin ... effectively patients with early stages of melanoma. ,A ... Hopkins University, found a gene known as Id1 that causes ... suppressor gene that ordinarily keeps precancerous moles from progressing to ...
    ... developed by Australians which may replace the PAP smear, it ... well as Australia. ,Sydney-based Polartechnics Ltd has developed the ... it offers instant results and greater ccuracy than PAP smears. ... directly from the cervix about the colour// and electrical properties ...
    ... the development of an artificial vision system for a ... acuity of about 20/400. ,The system uses ... both of which are mounted on a pair of ... miniature computer which is worn on a belt. After ...
    Cached Medicine News:Health News:Discovery of World’s smallest laser 2Health News:Prostratin- Drug to eradicate HIV 2Health News:Arthritis risk reduced by exercise 2Health News:Gene causes moles to become cancerous 2
    Hydrodissection / Aspiration Cannula, 25 g. Straight with U-tip. U-shaped tip allows aspiration and irrigation at the 12 o'clock position. Overall length 18 mm. 5/box....
    Hydrodissection / Aspiration Cannula, 25 g. Angled with left hook. 10 mm angled shaft with 2.5 mm left hook tip. Overall length 20 mm. 5/box....
    Retinal Hydrodissection Cannula. 20 gauge shaft tapers to 41 gauge I.D. flexible tip. Packaged sterile. 5/Box....
    Posterior Capsule Polisher, 23 g., 30 angle small gauge with roughened tip, open end port. Overall length 16 mm. 5/box....
    Medicine Products: